Ensign Peak Advisors, Inc Coherus Bio Sciences, Inc. Transaction History

Ensign Peak Advisors, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$7.17 - $13.87 $9,966 - $19,279	1,390 Added 6.92%	21,490 $207,000
Q3 2021 Nov 12, 2021	BUY	$12.68 - $17.79 $82,420 - $115,635	6,500 Added 47.79%	20,100 $323,000
Q2 2021 Aug 13, 2021	BUY	$12.95 - $15.41 $25,900 - $30,820	2,000 Added 17.24%	13,600 $188,000
Q4 2020 Feb 12, 2021	BUY	$16.56 - $18.94 $192,095 - $219,704	11,600 New	11,600 $202,000
Q2 2020 Aug 12, 2020	SELL	$14.43 - $19.16 $49,884 - $66,236	-3,457 Closed	0 $0
Q1 2020 May 11, 2020	SELL	$11.67 - $22.53 $166,612 - $321,660	-14,277 Reduced 80.51%	3,457 $56,000
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $289,596 - $378,975	17,734 New	17,734 $319,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.